AstraZeneca Results Presentation Deck

Q1 2021: solid start to the year Oncology and New CVRM drove growth Oncology New CVRM Respiratory & Immunology Other medicines Total revenue excl. vaccine Pandemic COVID-19 vaccine Total revenue Growth across disease areas Total revenue at actual exchange rates; changes at CER. 9 Q1 2021 $m 3,024 1,306 1,546 1,169 7,045 275 7,320 growth % 16 15 (4) (4) 7 11 ratio % 41 18 21 16 96 100 EMs¹ - EMS ex China - China US Europe Established rest of world Total revenue Growth across geographies Q1 2021 $m 2,592 913 1,679 2,310 1,546 872 7,320 Total revenue at actual exchange rates; changes at CER. 1. Emerging markets. growth % 10 11 10 10 18 5 11 ratio % 35 12 23 32 21 12 100 B

View entire presentation